Table 1 Baseline characteristics of patients treated with Rivaroxaban or Dabigatran

Age (y), mean (SD)

55 (14)

55 (13)

0.828

Sex (male), n (%)

38 (73)

23 (55)

0.111

Esophageal varices F1/F2/F3, n (%)

30/9/1 (32/10/1)

28/4/1 (30/4/1)

0.849

Beta-blocker therapy, n (%)

15 (29)

12 (29)

0.977

Etiology of cirrhosis, n (%)

0.314

 Alcohol

14 (27)

6 (14)

 HBV

28 (54)

21 (50)

 HCV

1 (2)

1 (2)

 Autoimmune

3 (6)

8 (19)

 NASH

2 (4)

1 (2)

 Other

4 (8)

5 (12)

Child–Pugh score, mean (SD)

7.1 (1.1)

6.9 (1.2)

0.284

MELD score, mean (SD)

9.0 (7.0–10.5)

8.4 (7.4–10.7)

0.834

D-dimer (ug/mL),(IQR)

1.7 (0.8–3.2)

2.8 (0.9–5.1)

0.127

INR − median (IQR)

1.2 (1.1–1.4)

1.2 (1.1–1.4)

0.083

Total bilirubin (umol/L), mean (SD)

23 (23)

22 (20)

0.667

Albumin (g/L), mean (SD)

29 (5)

30 (5)

0.468

Creatinine (mmol/L), mean (SD)

67.2 (18.9)

65 (17.6)

0.56

GFR (mL/ min), mean (SD)

104 (23)

101 (21)

0.396

Platelet (x10^9/L), (IQR)

126 (63–203)

179 (66–258)

0.115

Duration of LMWH bridging therapy

1 (1–2)

1 (1–2)

0.615

Yerdel classification, n (%)

0.637

 Grade I

15 (19)

11 (26)

 Grade II

11 (21)

11 (26)

 Grade III

10 (19)

12 (27)

 Grade IV

16 (31)

8 (11)

Complete occlusive thrombus, n (%)

12 (23)

9 (21)

0.849